Cascadian Therapeutics, Inc.
CASC
CASC was delisted on the 8th of March, 2018.
93 hedge funds and large institutions have $155M invested in Cascadian Therapeutics, Inc. in 2015 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 43 reducing their positions, and 18 closing their positions.
201% more call options, than puts
Call options by funds: $890K | Put options by funds: $296K
7% less funds holding
Funds holding: 100 → 93 (-7)
27% less capital invested
Capital invested by funds: $211M → $155M (-$56.2M)
28% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 18
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
51% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$22.6M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$3.58M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.22M |
| 4 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$787K |
| 5 |
PA
Perceptive Advisors
New York
|
+$683K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$3.79M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.51M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$2.24M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$2.16M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$1.88M |
CASC Hedge Fund Activity: Q3 2015 in Review
93 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q3 2015, worth a combined $155M — down 27% from $211M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CASC and 13 opened new positions — a net loss of 5 holders — while 43 trimmed existing stakes and 21 added.
The largest buyer was BVF Inc, adding an estimated $22.6M. The largest seller was Broadfin Capital, cutting an estimated $3.79M.
- 93 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q3 2015, down from 100 in Q2 2015.
- Funds reported $155M of Cascadian Therapeutics, Inc. stock for Q3 2015, down 27% quarter-over-quarter.
- 13 funds opened new Cascadian Therapeutics, Inc. positions in Q3 2015 and 18 closed out, a net change of -5 holders.
- The largest Cascadian Therapeutics, Inc. buyer in Q3 2015 was BVF Inc, an estimated $22.6M added.
- The largest Cascadian Therapeutics, Inc. seller in Q3 2015 was Broadfin Capital, an estimated $3.79M sold.
Based on aggregated 13F filings for Q3 2015.